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MaBACKGROUND Symptoms and survival of patients with carcinoid syndrome have improved, but development of
carcinoid heart disease (CaHD) continues to decrease survival.
OBJECTIVES This study aimed to analyze patient outcomes after valve surgery for CaHD during a 27-year period at
1 institution to determine early and late outcomes and opportunities for improved patient care.
METHODS We retrospectively studied the short-term and long-term outcomes of all consecutive patients with CaHD
who underwent valve replacement at our institution between 1985 and 2012.
RESULTS The records of 195 patients with CaHD were analyzed. Pre-operative New York Heart Association class was
III or IV in 125 of 178 patients (70%). All had tricuspid valve replacement (159 bioprostheses, 36 mechanical), and
157 underwent a pulmonary valve operation. Other concomitant operations included mitral valve procedure (11%), aortic
valve procedure (9%), patent foramen ovale or atrial septal defect closure (23%), cardiac metastasectomies or biopsy
(4%), and simultaneous coronary artery bypass (11%). There were 20 perioperative deaths (10%); after 2000, periop-
erative mortality was 6%. Survival rates (95% conﬁdence intervals) at 1, 5, and 10 years were 69% (63% to 76%),
35% (28% to 43%), and 24% (18% to 32%), respectively. Overall mortality was associated with older age, cytotoxic
chemotherapy, and tobacco use; 75% of survivors had symptomatic improvement at follow-up. Presymptomatic valve
operation was not associated with late survival beneﬁt.
CONCLUSIONS Operative mortality associated with valve replacement surgery for CaHD has decreased. Symptomatic
and survival beneﬁt is noted in most patients when CaHD is managed by an experienced multidisciplinary team.
(J Am Coll Cardiol 2015;66:2189–96) © 2015 by the American College of Cardiology Foundation.D uring the past 30 years, new medical andsurgical treatments have emerged for ma-lignant carcinoid syndrome. Medical thera-
pies have targeted the symptom complex of carcinoid
syndrome through the use of the somatostatin
analogue octreotide. Surgical therapies have tar-
geted hepatic metastases with dearterialization,
resection, debulking, and liver transplantation.
These treatments have improved symptoms and
longevity in patients with carcinoid syndrome (1–7);
however, for patients with cardiac involvement,m the *Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Mi
nic, Rochester, Minnesota; zDivision of Cardiovascular Anesthesia, M
cology, Mayo Clinic, Rochester, Minnesota; kDivision of Biomedical Stat
sota; and the {University of Wisconsin School of Medicine and Public Hea
t they have no relationships relevant to the contents of this paper to dis
nuscript received March 10, 2015; revised manuscript received July 24, 2right-sided heart failure worsens their quality of
life and leads to excess mortality. Valve surgery is
the only effective treatment option for patients
with symptomatic carcinoid heart disease (CaHD)
and improves survival (8). Without operation, only
10% of patients survive 2 years after the onset of
New York Heart Association (NYHA) functional class
III or IV symptoms (9).
In this study, we evaluated short-term and long-
term outcomes after valve replacement surgery in
195 consecutive patients with CaHD at 1 institution,nnesota; yDivision of Cardiovascular Surgery, Mayo
ayo Clinic, Rochester, Minnesota; xDepartment of
istics and Informatics, Mayo Clinic, Rochester, Min-
lth, Madison, Wisconsin. The authors have reported
close.
015, accepted September 2, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
CaHD = carcinoid heart disease
CI = conﬁdence interval
NYHA = New York Heart
Association
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previously reported our initial experience
with 26 patients (9).
METHODS
PATIENTS. The Mayo Clinic Institutional Re-
view Board approved the study. Between November
1985 andDecember 2012, 195 consecutive patients with
CaHD underwent valve surgery at the Mayo Clinic,
Rochester, Minnesota, in an attempt to improve
symptoms and survival. We retrospectively reviewed
the pre-operative characteristics, intraoperative man-
agement, and operative outcomes of these patients.SEE PAGE 2197CLINICAL AND LABORATORY FINDINGS. A compre-
hensive pre-operative clinical evaluation was per-
formed that included echocardiography in all
patients. All patients were cared for by a multidisci-
plinary team that included a medical oncologist,
cardiologist, cardiac anesthesiologist, and cardiac
surgeon. Coronary angiography was performed pre-
operatively when applicable (10).
The usual initial pre-operative dose of octreotide
was 150 mg, administered subcutaneously every 8 h.
Since the introduction and use of the octreotide
long-acting release formulation (Sandostatin, Novar-
tis, Basel, Switzerland) in 1999 (11), most patients
received this agent, typically 20 mg intramuscularly
every 28 days, with higher long-acting release and
supplementary short-acting doses administered for
breakthrough symptoms or tachyphylaxis.
Because of the known poor prognosis of patients
with severe symptomatic CaHD, patients were
screened for cardiac disease. Valve surgerywas offered
to patients who had symptomatic severe CaHD, pro-
gressive right-sided cardiac chamber enlargement or
dysfunction, or severe hepatic involvement requiring
surgery with increased right atrial pressure (12).
Patients with CaHD and severe tricuspid valve
regurgitation who underwent echocardiography at
the Mayo Clinic during the same time period but did
not have an operation were identiﬁed through the
echocardiography laboratory database. The reason
they did not have valve replacement at the Mayo
Clinic was recorded.
SURGICAL MANAGEMENT. Treatment was not ran-
domized. Initially, mechanical prostheses were rec-
ommended for tricuspid valve replacement because
of the reported carcinoid involvement of a porcine
bioprosthesis (13). Over time, bioprostheses were
increasingly used in patients considered to be at
high risk for anticoagulation-related complications;because of the generally favorable short-term out-
comes in these patients, bioprostheses were used
more frequently.
Pulmonary valve intervention was performed if
pulmonary valve disease was present. In our early
experience, pulmonary valvectomy was preferred.
Subsequently, long-standing severe pulmonary valve
regurgitation that occurred after this procedure was
recognized to adversely affect right ventricular
remodeling. Since 2002, the pulmonary valve has
been routinely replaced when involved by CaHD (14).
Meticulous pre-operative planning and periopera-
tive care were instituted for patients with CaHD to
prevent life-threatening carcinoid crises (15) or to
institute early therapy should a crisis occur intra-
operatively. Anesthetic management aimed to limit
hemodynamic perturbations associated with carci-
noid reactions, primarily through the use of intrave-
nous octreotide and vasopressors, as well as to initiate
aggressive therapy for long-standing right-sided heart
failure with hemoﬁltration and diuresis (15–17).
Intravenous octreotide acetate was used if ﬂushing,
unexplained hemodynamic lability, or volume loss
occurred during extracorporeal circulation (17).
PATHOLOGICAL FINDINGS. The surgical pathology
reports were reviewed to assess the gross and
microscopic pathology of the native valves and the
explanted prostheses in patients who underwent
reoperation (18).
OUTCOMES. Follow-up data were obtained by review
of medical records. Perioperative death was deﬁned
as death within 30 days of operation or during the
same hospital stay. The Social Security Index was
used to determine whether patients who had not
returned for follow-up were alive or dead.
STATISTICAL METHODS. Descriptive statistics for
categorical variables are reported as frequency (per-
centage) and continuous variables as mean  standard
deviation or median and range. Thirty-day mortality
was compared between surgical eras by use of the
Fisher exact test.
The Kaplan-Meier method was used to calculate 1-,
5-, and 10-year survival and freedom from reopera-
tion statistics. Cox regression models were used to
ﬁnd the univariate and multivariate predictors of
overall mortality and reoperation. The multivariate
model considered univariately signiﬁcant variables
(p < 0.05), with model selection using the stepwise
method (backward and forward methods resulted in
the same model). All statistical tests were 2-sided,
and p < 0.05 was considered statistically signiﬁcant.
SAS software version 9.3 (SAS Institute, Inc., Cary,
North Carolina) was used for statistical analysis.
TABLE 2 Surgical Features (N ¼ 195)
CPB time, min 88  37 (16–205)
Tricuspid valve replacement only 83  34
Tricuspid valve replacement with other
valve operation
127  37
Tricuspid valve replacement
Mechanical 36 (18)
Bioprosthesis 159 (82)
Tricuspid valve size, mm 31 (25–34)
Pulmonary valve replacement 107 (55)
Mechanical 6 (6)
Bioprosthesis 101 (94)
Pulmonary valve size, mm 25 (19–31)
Pulmonary valvectomy 50 (26)
Mitral valve prosthesis 16 (8)
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2191RESULTS
CLINICAL AND DIAGNOSTIC DATA. During the
study period, 195 patients with CaHD (98 men;
mean age 61  11 years) underwent valve surgery.
Patients’ preoperative clinical features are shown in
Table 1. Most patients had primary carcinoid disease
in the intestine with hepatic metastasis. Four pa-
tients had primary ovarian carcinoid tumor without
hepatic metastasis (19,20). The mean time from
diagnosis of carcinoid tumor to the valve operation
was 4.7  6.0 years. The NYHA functional class was
III or IV in 125 patients (70%). Octreotide therapy
was used before operation in 184 patients (94%)
(Table 1).
All patients had severe tricuspid valve regurgita-
tion. Pulmonary, mitral, or aortic valve disease that
warranted intervention was detected in 157, 21, and 18
patients, respectively. Signiﬁcant coronary artery
disease (stenosis $50% diameter) was present in 27
patients who underwent pre-operative coronary
angiography.
During the same time period, 108 patients had
CaHD and severe tricuspid valve regurgitation iden-
tiﬁed by echocardiography at our institution but did
not have an operation at the Mayo Clinic. Of those
108 patients, 39 (36%) were asymptomatic or mini-
mally symptomatic, 6 (6%) underwent valve
replacement elsewhere, 10 (9%) died before cardiac
consultation or intervention, 9 (8%) were lost to
follow-up, and 8 (7%) declined intervention. Thirty-
six (33%) were not believed to be surgical candidates
for the following reasons: comorbid conditions (n ¼
17), extensive metastatic disease (n ¼ 14), left ven-
tricular dysfunction (n ¼ 3), age (n ¼ 1), or religious
objections (n ¼ 1).TABLE 1 Pre-Operative Clinical Features (N ¼ 195)
Men 98 (50)
Age at cardiac surgery, yrs 61  11
62 (25–87)
NYHA functional class (n ¼ 178)
I or II 53 (30)
III or IV 125 (70)
Creatinine, mg/dl 1.2  0.4
Other chemotherapy for carcinoid disease 47 (24)
Octreotide therapy 184 (94)
Dose per 24 h
Short-acting, mg 750 (200–3,000)
LAR, mg 30 (20–120)
Time from carcinoid diagnosis to valve
surgery, yrs (n ¼ 118)
4.7  6
2.4 (0–41)
Values are n (%), mean  SD, or median (range).
LAR ¼ octreotide long-acting release formulation; NYHA ¼ New York Heart
Association.SURGICAL MANAGEMENT. Surgical data are pre-
sented in Table 2. Tricuspid valve replacement
involved bioprostheses in 159 patients and mechani-
cal valves in 36; median valve size was 31 mm. Pul-
monary valve intervention was performed in 157
patients: 50 had pulmonary valvectomy with outﬂow
tract enlargement, and 107 had pulmonary valve
replacement.
Concomitant CaHD with moderate or greater
regurgitation prompted mitral valve repair in 5 pa-
tients and mitral valve replacement in 16 patients.
Three patients had aortic valve repair, and 15 had
aortic valve replacement. Seven patients underwent
quadruple valve replacement (21). Coronary artery
bypass grafting surgery was also performed in 22
patients. Eleven patients (6%) required permanent
pacemaker implantation for persistent post-operative
heart block.
The mean cardiopulmonary bypass time was
88  37 min, and cross-clamp time was 30  30 min.
Large doses of octreotide were often required; theMechanical 5 (31)
Bioprosthesis 11 (69)
Mitral valve size, mm 27 (25–29)
Mitral valve repair 5 (3)
Aortic valve prosthesis 15 (8)
Mechanical 5 (33)
Bioprosthesis 10 (67)
Aortic valve size, mm 21 (19–27)
Aortic valve repair 3 (2)
PFO or ASD closure 45 (23)
Cardiac metastasis biopsied or removed 8 (4)
Simultaneous coronary artery bypass surgery 22 (11)
Octreotide dose during operation, mg 0.5 (0.0–2.1)
Pacemaker 11 (6)
Time in hospital, days 9  7
Death in hospital or within 30 days 20 (10)
Values are mean  SD (range), n (%), or median (range).
ASD ¼ atrial septal defect; CPB ¼ cardiopulmonary bypass; PFO ¼ patent
foramen ovale.
TABLE 3 Univariate and Multivariate Predictors of Overall Mortality
Predictor
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
Age 1.03 (1.01–1.04) <0.001 1.02 (1.01–1.04) <0.01
Higher pre-operative creatinine 1.70 (1.04–2.79) 0.03
Longer time from carcinoid diagnosis
to valve operation
1.02 (0.99–1.04) 0.25
Higher EF 0.99 (0.97–1.00) 0.13
Female 0.77 (0.55–1.08) 0.13
Year of surgery
1990–1999 0.73 (0.37–1.44) 0.37
2000–2009 0.56 (0.29–1.10) 0.09
2010–2012 0.79 (0.32–1.94) 0.61
Pre-operative NYHA functional
class III or IV
1.63 (1.07–2.49) 0.02
Loop diuretic agents
Not used 0.81 (0.58–1.14) 0.23
Higher dose 1.16 (0.83–1.61) 0.40
Higher oral dose 0.95 (0.67–1.34) 0.77
IV furosemide 1.67 (1.08–2.58) 0.02
Somatostatin therapy 2.15 (0.94–4.88) 0.07
Pre-operative chemotherapy 1.48 (1.04–2.11) 0.03 1.48 (1.03–2.11) 0.03
Nonpharmacological treatment of
metastatic disease
0.78 (0.55–1.10) 0.15
Ascites 1.48 (1.06–2.08) 0.02
Leg edema 1.32 (0.90–1.94) 0.16
Pre-operative diabetes mellitus 1.88 (1.05–3.34) 0.03
Pre-operative hypertension 1.06 (0.76–1.49) 0.71
Pre-operative tobacco use 1.96 (1.40–2.75) <0.001 1.71 (1.21–2.42) <0.01
Pre-operative CAD 1.39 (0.95–2.04) 0.09
PVR 0.82 (0.59–1.15) 0.26
Mechanical valve 1.43 (0.96–2.11) 0.08
Moderate or greater MV or AV
regurgitation
1.69 (1.08–2.64) 0.02
Larger RV size 0.50 (0.30–0.83) 0.008
Reduced RV systolic function 1.59 (1.00–2.52) 0.049
Moderate or greater PV regurgitation 1.15 (0.75–1.76) 0.52
Higher Charlson index 1.02 (0.96–1.08) 0.52
Isolated TVR 0.98 (0.54–1.78) 0.95
AV ¼ aortic valve; CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; EF ¼ ejection fraction; HR ¼ hazard
ratio; IV ¼ intravenous; MV ¼ mitral valve; NYHA ¼ New York Heart Association; PV ¼ pulmonary valve;
PVR ¼ pulmonary valve replacement; RV ¼ right ventricle; TVR ¼ tricuspid valve replacement.
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perioperative period was 0.5 mg (range 0 to 2.1 mg).
The overall mean hospital stay was 9  7 days.
VALVE PATHOLOGY. Examination of the explanted
valves demonstrated gross cusp thickening without
calciﬁcation. Thickening was attributable to cellular
proliferation and deposition of extracellular matrix,
which comprised collagen, myxoid ground substance,
and elastin. Carcinoid plaque involved the tricuspid
and mitral valve leaﬂets, tendinous cords, and
papillary muscles. Excised pulmonary and aortic
valve cusps also demonstrated carcinoid plaques.
Microscopic examination of the explanted tri-
cuspid bioprostheses demonstrated degenerating andorganizing thrombus without typical carcinoid pla-
ques in 4 patients, pannus in 1 patient, and normal
appearance in 2 patients (whose bioprostheses were
replaced at the time of pulmonary valve replacement
for pulmonary valve regurgitation). One patient had
microscopic features of bioprosthetic carcinoid pla-
que deposition with associated prosthetic valve
dysfunction at the time of reoperation, more than
8 years after initial valve replacement.
SURVIVAL AND OUTCOMES. Univariate predictors of
perioperative death included era of operation (higher
mortality before 2000), need for pre-operative loop
diuretic therapy, mechanical valve replacement, and
longer cardiopulmonary bypass time (data not
shown). By multivariate analysis, era of operation and
need for intravenous loop diuretic therapy were
related to perioperative mortality (data not shown).
The overall operative mortality was 10%. The
surgical deaths were not equally distributed over the
27-year period: mortality was highest before 1990 (2
of 10, or 20%) and decreased in each subsequent
decade. Of the 20 perioperative deaths, 12 occurred
in the ﬁrst 71 patients (before 2000; 17%). Since
2000, 8 perioperative deaths occurred in 124 pa-
tients (6%): 7 of 97 (7.2%) occurred between 2000
and 2009, and 1 of 27 (3.7%) occurred between 2010
and 2012.
Survival at 1, 5, and 10 years was 69% (95% conﬁ-
dence interval [CI]: 63% to 76%), 35% (95% CI:
28% to 43%), and 24% (95% CI: 18% to 32%), respec-
tively. Maximal survival to date is 19.5 years after
valve replacement for CaHD. Univariate predictors of
mortality included patient age, pre-operative serum
creatinine value, pre-operative NYHA functional
class, use of intravenous furosemide, pre-operative
chemotherapy, presence of ascites, diabetes mellitus,
pre-operative tobacco use, left-sided valve disease,
and right-sided heart size and function (Table 3).
By multivariate analysis, older age, pre-operative
chemotherapy, and pre-operative tobacco use re-
mained signiﬁcant predictors of mortality during
follow-up. Survival did not differ by type of valve used
(p ¼ 0.08) (Figure 1).
During follow-up, 17 patients had reoperation, with
some patients having more than 1 procedure: 8
tricuspid bioprosthesis replacements, 8 pulmonary
valve replacements (3 after initial pulmonary valve-
ctomy), 5 pericardiectomies, 1 mechanical tricuspid
prosthesis replacement, and 1 emergent pulmonary
valve replacement for pulmonary artery rupture
during attempted homograft balloon valvuloplasty.
Survival free from reoperation was not related to
prosthesis type (p ¼ 0.22) (Figure 2). At reoperation
for bioprosthesis dysfunction, 7 valves were replaced
FIGURE 1 Survival by Tricuspid Valve Prosthesis Type
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FIGURE 2 Freedom From Reoperation by Valve Type
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2193with mechanical prostheses. One of the patients
included in this series had percutaneous valve-in-
valve tricuspid and pulmonary valve replacement
for prosthesis dysfunction.
In 1 patient, a thrombus developed on a mechanical
tricuspid prosthesis related to inadequate systemic
anticoagulation; this caused dyspnea and an in-
crease in transvalvular gradient. The thrombus was
successfully treated with intravenous thrombolytic
therapy.
Among patients with signiﬁcant limiting pre-
operative symptoms (NYHA functional class III or IV),
symptomatic improvement was noted in 69 of 92
patients (75%), and 118 of 155 patients (76%) were in
NYHA functional class I or II at follow-up.
DISCUSSION
In this series of 195 consecutive surgically treated
patients with CaHD, operative risk, patient selection,
post-operative symptoms, and long-term survival
have improved with time and experience of our
specialized multidisciplinary team. In our initial sur-
gical experience with CaHD (9) and in reports from
other centers (22–24), the perioperative risk of valve
replacement in patients with CaHD was high. We
subsequently reﬁned our approach to carcinoid syn-
drome and CaHD. With increased experience and a
multidisciplinary approach, operative mortality
decreased in our series from 20% before 1990 to <5%
(Central Illustration). Our operative mortality com-
pares favorably with reports from before 2012, which
ranged from 18% to 63% (22–24).
Post-operative survival among patients with CaHD
has also improved over time. Survival is markedly
improved compared with medically managed histor-
ical control subjects with NYHA functional symptoms
greater than class II: only 10% of those patients sur-
vived 2.5 years (8,9). The current series also demon-
strates favorable survival (Figure 1) compared with
our early surgical series (9). Post-operatively, most
patients had symptomatic improvement, with sur-
vival up to 19.5 years after valve replacement. Lack of
improvement in functional status after operation was
related to tumor progression in some patients; others
appeared to have systolic or diastolic right-sided
heart failure with or without pericardial effusion or
constriction.
Because of the known poor prognosis related to
severe symptomatic CaHD, we decided to evaluate
patients annually for cardiac involvement. Echocar-
diography was performed in patients with signs or
symptoms of cardiac disease. A multidisciplinary
team approach (8) allowed us to reﬁne indications foroperation. We offered valve surgery to both symp-
tomatic patients with severe CaHD and asymptomatic
or minimally symptomatic patients with progressive
right-sided heart enlargement or dysfunction. We
also referred some asymptomatic patients with severe
CaHD for correction of valve regurgitation before
partial hepatectomy or liver transplantation. Liver
operation carries excess risk in patients with CaHD
with high right atrial pressure (12). We avoid valve
replacement surgery in patients with end-stage met-
astatic disease and in those with poorly controlled
systemic carcinoid symptoms despite octreotide
therapy or hepatic dearterialization.
CENTRAL ILLUSTRATION Surgical Treatment Outcomes in Carcinoid Heart Disease:
30-Day Mortality by Surgical Era
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2194A major clinical challenge in patients with CaHD is
the difﬁculty distinguishing symptoms of right-sided
heart failure from end-stage metastatic carcinoid dis-
ease, because both can present with progressive fa-
tigue, edema, and ascites. Clinical status after valve
replacement serves as the conﬁrmatory clinical tool,
but operation carries an excess risk of morbidity and
decreased post-operative survival when pre-operative
symptoms are primarily related to advanced metasta-
tic disease. Improved pre-operative tools are needed
for continued reﬁnement of risk stratiﬁcation. This
will most likely require a comprehensive assessment
of tumor burden, nutritional status, cardiac disease,
and the potential for future tumor management.
Mechanical valve prostheseswere used for tricuspid
valve replacement in our early experience because of
the reported carcinoid involvement of a porcine bio-
prosthesis (13). Over time, we used bioprosthesesmore
often in patients considered to be at higher than
normal risk for anticoagulation-related complications;
the generally favorable short-term outcome in these
patients led us to use bioprostheses more liberally.
In addition, pathological review of explanted bio-
prostheses suggested that carcinoid involvement was
an uncommon reason for valve dysfunction requiring
reoperation; it was found in only 1 explanted bio-
prosthesis in our series.
The most frequent cause of tricuspid biopro-
sthesis dysfunction in our patients was thrombus.Identiﬁcation of thrombus on dysfunctional explanted
bioprostheses resulted in a protocol change. We now
recommend post-operative vitamin K antagonist
anticoagulation for 3 months and periodic echocar-
diographic surveillance of the prosthetic valves after
cessation of anticoagulation. Reversal of bioprosthesis
dysfunction has been noted in patients with CaHDwith
reinitiation of vitamin K antagonist anticoagulation
(25). When reoperation is required for bioprosthetic
valve dysfunction related to carcinoid or thrombus
formation, a mechanical prosthesis is advised when
vitamin K antagonist anticoagulation can be toler-
ated (26). Alternatively, percutaneous valve-in-valve
replacementmay be considered for select patients (27).
Since 2002, we have routinely replaced the pul-
monary valve when CaHD affected it because of the
incomplete right ventricular remodeling recognized
in patients with long-standing severe pulmonary
valve regurgitation (14). Homografts were used to
replace the pulmonary valve early in our experience;
however, in several patients, we identiﬁed premature
dysfunction related to constriction of the homograft.
We now favor placement of a large stented bio-
prosthesis, facilitated with patch enlargement of the
pulmonary valve annulus and outﬂow tract. Rarely, a
mechanical prosthesis is used for tricuspid valve
replacement (26). In this setting when pulmonary
valve replacement is indicated, a mechanical pulmo-
nary prosthesis is preferred over bioprosthesis (28).
PERSPECTIVES
COMPETENCYINMEDICALKNOWLEDGE:Mostpatientswith
symptomatic carcinoid valvular heart disease beneﬁt from valve
replacement surgery in terms of both survival and symptoms.
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Valve replacement surgery should be considered for
patients with symptomatic carcinoid heart disease before they
develop advanced right-sided heart failure.
TRANSLATIONAL OUTLOOK: Future studies should seek to
deﬁne imaging and biomarker strategies to distinguish right-
sided heart failure from end-stage metastatic carcinoid disease
and to guide timing of valve replacement surgery.
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2195In our patients with CaHD, multivariate analysis
showed that perioperative mortality was related to
the era of operation and the need for pre-operative
intravenous diuretic therapy. These ﬁndings demon-
strate that surgical survival has improved during our
experience. This likely reﬂects a combination of
improved patient selection, experience of the multi-
disciplinary team, progress in the management of the
underlying malignancy, and possible advances in
surgical and valve technology. In the past, right-sided
valve surgery was performed relatively late in the
natural history of the disease and on patients with
features of advanced right-sided heart failure (10,29).
Increasingly, data suggest survival beneﬁt with
presymptomatic surgical intervention for left-sided
valve disorders (10). By univariate analysis, advanced
NYHA functional class was associated with decreased
long-term survival in our series. However, by multi-
variate analysis, long-term survival beneﬁt was not
detected with presymptomatic surgical intervention.
This most likely reﬂects the comorbid malignancy that
independently decreases life expectancy.
Our multivariate analysis suggests that patients
with carcinoid disease and anasarca who require hos-
pitalization and intravenous diuretic treatment before
operation have decreased perioperative survival. In
addition, older patients, thosewith a history of tobacco
use, and those with carcinoid disease treated with
chemotherapy other than octreotide before valve
operation also had reduced survival. These patients
represent the group with the most advanced disease
and highest risk. Some of these patients have end-
stage metastatic carcinoid disease that affects sur-
vival more than right-sided heart failure from CaHD.
STUDY LIMITATIONS. These data must be interpreted
in light of the retrospective, nonrandomized study
design and a component of referral bias. Patients with
carcinoid syndrome pose a clinical challenge, because
it is often difﬁcult to objectify pre-operative func-
tional status as a result of isolated right-sided heart
disease and comorbid malignancy. Unfortunately, a
subset of the patients referred to our center forconsideration of valve surgery are severely symp-
tomatic with advanced carcinoid disease and
anasarca, which results in poor operative risk and
decreased post-operative survival.
CONCLUSIONS
CaHD decreases survival in patients with carcinoid
syndrome. These patients have multivalve disease
and comorbid conditions. Despite this complexity,
symptomatic patients with CaHD and controlled sys-
temic disease who are referred for valve surgery have
an acceptable perioperative risk when treated at
an experienced center by a multidisciplinary team.
Valve operation before the onset of advanced sym-
ptoms carries a survival beneﬁt for this population
compared with operation performed for more ad-
vanced symptoms. Symptomatic improvement is
noted in the majority.
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